Abstract
SummaryCellular senescence is a driver of many age-related pathologies. There is an active search for pharmaceuticals termed senolytics that can mitigate or remove senescent cells in vivo by targeting genes that promote the survival of senescent cells. We utilized single-cell RNA sequencing to identify CRYAB as a robust senescence-induced gene and potential target for senolysis. Using chemical inhibitor screening for CRYAB disruption, we identified 25-hydroxycholesterol (25HC), an endogenous metabolite of cholesterol biosynthesis, as a potent senolytic. We then validated 25HC as a senolytic in mouse and human cells in culture and in vivo in mouse skeletal muscle. Thus, 25HC represents a potential class of senolytics, which may be useful in combating diseases or physiologies in which cellular senescence is a key driver.
Highlights
Cellular senescence causes proliferative cells to undergo an essentially permanent cell-cycle arrest upon encountering stressful stimuli such as genotoxic chemotherapy, radiation, or telomere shortening (Bernadotte et al, 2016; Demaria et al, 2017; Limbad et al, 2020)
There is an active search for pharmaceuticals termed senolytics that can mitigate or remove senescent cells in vivo by targeting genes that promote the survival of senescent cells
Using chemical inhibitor screening for CRYAB disruption, we identified 25-hydroxycholesterol (25HC), an endogenous metabolite of cholesterol biosynthesis, as a potent senolytic
Summary
Cellular senescence causes proliferative cells to undergo an essentially permanent cell-cycle arrest upon encountering stressful stimuli such as genotoxic chemotherapy, radiation, or telomere shortening (Bernadotte et al, 2016; Demaria et al, 2017; Limbad et al, 2020). There is an active search for drugs that can kill senescent cells (senolytics) (van Deursen, 2019). This class of drugs improves health span in multiple contexts of aging, and has potential to mitigate many age related diseases (Chang et al, 2016; Fuhrmann-Stroissnigg et al, 2017; Kim and Kim, 2019; Kirkland and Tchkonia, 2017; Wissler Gerdes et al, 2020; Xu et al, 2018). The potential benefits of ABT as a senolytic were studied after skeletal muscle injury (Chiche et al, 2017), but no benefits were reported in aging skeletal muscle
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
